Clinical Trial Update: Consolidation Sintilimab After Concurrent Chemoradiation in Patients With Unresectable Stage III NSCLC [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update evaluating consolidation sintilimab after concurrent chemoradiation in patients with unresectable stage III non-small cell lung ca…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Sintilimab (sintilimab)

Snippet

Sponsor: Shandong Cancer Hospital and Institute | Conditions: Carcinoma, Non-Small Cell Lung | Phase 3 | Status: UNKNOWN